PARG inhibitor sensitivity correlates with accumulation of single-stranded DNA gaps in preclinical models of ovarian cancer
Open Access
- 15 November 2024
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 121 (47)
Abstract
Poly (ADP-ribose) glycohydrolase (PARG) is a dePARylating enzyme which promotes DNA repair by removal of poly (ADP-ribose) (PAR) from PARylated proteins. Loss or inhibition of PARG results in replication stress and sensitizes cancer cells to DNA-damaging agents. PARG inhibitors are now undergoing clinical development for patients having tumors with homologous recombination deficiency (HRD), such as cancer patients with germline or somaticBRCA1/2-mutations. PARP inhibitors kill BRCA-deficient cancer cells by increasing single-stranded DNA gaps (ssGAPs) during replication. Here, we report that, like PARP inhibitor (PARPi), PARG inhibitor (PARGi) treatment also causes an accumulation of ssGAPs in sensitive cells. PARGi exposure increased accumulation of S-phase-specific PAR, a marker for Okazaki fragment processing (OFP) defects on lagging strands and induced ssGAPs, in sensitive cells but not in resistant cells. PARGi also caused accumulation of PAR at the replication forks and at the ssDNA sites in sensitive cells. Additionally, PARGi exhibited monotherapy activity in specific HR-deficient, as well as HR-proficient, patient-derived, or patient-derived xenograft (PDX)-derived organoids of ovarian cancer, and drug sensitivity directly correlated with the accumulation of ssGAPs. Taken together, PARGi treatment results in toxic accumulation of PAR at replication forks resulting in ssGAPs due to OFP defects during replication. Regardless of theBRCA/HRD-status, the induction of ssGAPs in preclinical models of ovarian cancer cells correlates with PARGi sensitivity. Patient-derived organoids (PDOs) may be a useful model system for testing PARGi sensitivity and functional biomarkers.Keywords
Funding Information
- U.S National Institute of Health (R01HL052725;P01HL048546;)
- U.S National Institute of Health (P50 CA168504; P50CA240243)
- U.S Department of Defense (BM110181)
This publication has 75 references indexed in Scilit:
- ATR protects ongoing and newly assembled DNA replication forks through distinct mechanismsCell Reports, 2023
- PARP Inhibitors in Ovarian Cancer: A ReviewTargeted Oncology, 2023
- POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cellsCell Reports, 2022
- The role of dePARylation in DNA damage repair and cancer suppressionDNA Repair, 2019
- DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase InhibitorsCancer Cell, 2019
- Defining a Cancer Dependency MapCell, 2017
- Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolaseDNA Repair, 2017
- DNA Fiber Analysis: Mind the Gap!2017
- SIRT4 Inhibits Glutamate Dehydrogenase and Opposes the Effects of Calorie Restriction in Pancreatic β CellsCell, 2006
- Emetine allows identification of origins of mammalian DNA replication by imbalanced DNA synthesis, not through conservative nucleosome segregation.The EMBO Journal, 1991